Hiam Chemaitelly

Research interests

Publications

• Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

  The Lancet Infectious Diseases · 2023 · 10.1016/s1473-3099(23)00058-0

• Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

  Nature Communications · 2022 · 10.1038/s41467-022-30895-3

• Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant

  Clinical Infectious Diseases · 2022 · 10.1093/cid/ciac275

• Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

  New England Journal of Medicine · 2022 · 10.1056/nejmoa2203965

• Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants

  New England Journal of Medicine · 2022 · 10.1056/nejmc2209306

• Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

  New England Journal of Medicine · 2022 · 10.1056/nejmoa2200797

• Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmc2104974

• BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

  Nature Medicine · 2021 · 10.1038/s41591-021-01583-4

• mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

  Nature Medicine · 2021 · 10.1038/s41591-021-01446-y

• SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

  EClinicalMedicine · 2021 · https://doi.org/10.1016/j.eclinm.2021.100861

• Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

  JAMA · 2021 · https://doi.org/10.1001/jama.2021.19623

• Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

  Scientific Reports · 2021 · 10.1038/s41598-021-85428-7

• Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar

  JAMA Internal Medicine · 2021 · 10.1001/jamainternmed.2021.7949

• Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

  New England Journal of Medicine · 2021 · 10.1056/nejmc2110300

• Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses

  Vaccines · 2020 · 10.3390/vaccines8040668

• Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting

  Clinical Infectious Diseases · 2020 · https://doi.org/10.1093/cid/ciaa1846

• Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions

  BMC Medicine · 2019 · 10.1186/s12916-019-1285-x

• Seriously misleading results using inverse of Freeman‐Tukey double arcsine transformation in meta‐analysis of single proportions

  Research Synthesis Methods · 2019 · 10.1002/jrsm.1348

• Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions

  Scientific Reports · 2018 · 10.1038/s41598-017-17936-4

Current projects

No projects listed.